Tumor treatment by sustained intratumoral release of 5-fluorouracil: Effects of drug alone and in combined treatments

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1550-1557

  Berrada, Mohammed ^a   Yang, Zhi ^a   Lehnert, Shirley ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

5 Fluorouracil; Biodegradable polymer; cis DDP; Radiation

Indexed keywords

DRUG PRODUCTS; GAMMA RAYS; RADIOTHERAPY; TUMORS;

POLYMER IMPLANT;

ONCOLOGY;

CISPLATIN; COBALT 60; FLUOROURACIL; IODINE 125; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FIBROSARCOMA; GAMMA RADIATION; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TUMOR; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COBALT RADIOISOTOPES; COMBINED MODALITY THERAPY; FLUOROURACIL; IODINE RADIOISOTOPES; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYMERS; RADIATION-SENSITIZING AGENTS; RADIOMETRY; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036891106     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03740-9     Document Type: Article

References (49)

1. Grem J.L. Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol. 7:1997;249-259.
2. Scanlon K.J., Newman E.M., Lu Y., et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian cells. Proc Natl Acad Sci U S A. 83:1986;8923-8925.
3. Rich T.A. Irradiation plus 5-fluorouracil Cellular mechanisms of action and treatment schedules . Semin Radiat Oncol. 7:1997;267-273.
4. Moertel C.G., Childs D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of unresectable gastrointestinal cancer. Lancet. 2:1969;865-867.
5. Gunderson L.L., Collins R., Earle J.D., et al. Adjuvant treatment of rectal cancer Randomized prospective study of irradiation ± chemotherapy . Int J Radiat Oncol Biol Phys. 12:1986;169.
6. Prolongation of the disease free interval in surgically treated rectal carcinoma. N Engl J Med. 312:1985;1465.
7. Survival after post operative combination treatment. (Letter to editor) N Engl J Med. 315:1986;1294.
8. Menei P., Venier M.-C., Gamelin E., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. Cancer. 86:1999;324-330.
9. Chaney A.W., Eifel P.J., Logsdon M.D., et al. Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 45:1999;113-118.
10. Dasmahapatra K.S., Citrin P., Hill D.J., et al. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous cell cancer of the head and neck. J Clin Oncol. 3:1985;1486-1489.
11. Decker D.A., Drelichman A., Jacobs J., et al. Adjunct chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer. 51:1993;1353-1355.
12. Kish J.A., Weaver A., Jacobs J., et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent disseminated epidermoid cancer of the head and neck. Cancer. 53:1984;1819-1824.
13. Mercier R.J., Neal G.D., Mattox D.E., et al. Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer. 60:1987;2609-2612.
14. Thyss A., Schnieder M., Santini J., et al. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer. 54:1986;755-760.
15. Posner M.R., Belliveau J.F., Weitberg A., et al. Continuous infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. Cancer Treat Rep. 71:1987;975-977.
16. Kemeny N., Niedzwiecka D., Reichman B., et al. Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma Differences in two patient groups with similar response rates . Cancer. 63:1989;1065-1069.
17. Decker D.A., Kinzie J., Evans R., et al. Pilot study of combination 5-fluorouracil cisdiamminodichl; oroplatinumII, and radiation therapy for grade III and IV astrocytoma. Am J Clin Oncol. 10:1987;444-447.
18. Hidalgo O.F., Gonzalez F., Gil A., et al. 120 hours of simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol. 12:1989;397-401.
19. Koizumi W., Kurihara M., Sasai T., et al. A phase II study of combination therapy with 5-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer. 72:1993;658-662.
20. Moertel C.G., Rubin J., O'Connell M.J., et al. A phase II study of combine 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol. 4:1986;1053-1057.
21. Sadek H., Azli N., Wendling J.L., et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil and bleomycin. Cancer. 66:1990;1692-1696.
22. Esaki T., Nakano S., Tatsumoto T., et al. Inhibition by 5-fluorouracil of cisdiamminodichloroplatinum II-induced DNA interstrand cross-link removal in HST-human squamous cell carcinoma line. Cancer Res. 52:1992;6501-6506.
23. Keane T.E., Gingrich J.R., Rosner G., et al. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer Analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model . Cancer Res. 54:1994;475-481.
24. Schabel J.M., Trader M.W., Laster W.R., et al. cis-Dichloroammineplatinum (II) Combination chemotherapy and cross-resistance studies with tumors of mice . Cancer Treat Rep. 63:1979;1459-1473.
25. Wennerberg J., Biorklund A., Tropé C. The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 114:1988;162-167.
26. Leong K.W., Brott B.C., Langer R.J. Bioerodible poly anhydrides as drug carrier matrices. I. Characterization, degradation and release characteristics. J Biomed Mater Res. 19:1985;00-00.
27. Leong K.W., D'Amore P., Marletta M., et al. Bioerodible polyanhydrides as drug-carrier matrices. Biocompatibility and chemical reactivity. J Biomed Mater Res. 20:1986;51-64.
28. Walter K.A., Kahan M.A., Gur A., et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 54:1994;2207-2212.
29. Sipos E.P., Witham T.F., Ratan R., et al. Biothionine sulfoximine potentiates the antitumor effect of 4-hydroxycyclophosphamide when deliver locally in the intracranial 9L-glioma model. Proc Amer Assoc Cancer Res. 36:1995;308.
30. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intra-operative controlled delivery by biodegradable polymer of chemotherapy for recurrent gliomas. Lancet. 345:1995;1008-1012.
31. Yapp D.T.T., Lloyd D.K., Zhu J., et al. Tumor treatment by sustained intra-tumoral release of cisplatin Effects of drug alone and combined with radiation . Int J Radiat Oncol Biol Phys. 39:1997;497-504.
32. Yapp D.T.T., Lloyd D.K., Zhu J., et al. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int J Radiat Oncol Biol Phys. 42:1998;413-420.
33. Yapp D.T.T., Lloyd D.K., Zhu J., et al. Cisplatin delivery by biodegradable polymer implant, systemic injection and osmotic pump Differences in selected tissue distribution in C3H mice bearing subcutaneous RIF-1 tumors . Anticancer Drugs. 9:1998;791-796.
34. Yapp D.T.T., Lloyd D.K., Zhu J., et al. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Radiother Oncol. 53:1999;77-84.
35. Doiron A., Yapp D.T.T., Olivares M., et al. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res. 59:1999;3677-3681.
36. Twentyman P.R., Brown J.M., Gray J.W., et al. A new mouse tumor system (RIF-1) for comparison of end-point studies. J Natl Canc Inst. 64:1980;595-604.
37. Brown J.M., Twentyman P.R., Zamvil S.S. Response of the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Canc Inst. 64:1980;605-611.
38. 125I interstitial implants in the RIF-1 murine flank tumor An animal model for brachytherapy . Radiat Res. 91:1982;624-637.
39. Krishnaswamy V. Dose distribution around an I-125 seed source in tissue. Radiology. 126:1978;489-491.
40. Kirichenko A.V., Rich T.A., Newman R.A., et al. Potentiation of the murine Mca-4 carcinoma response by 9-amino-20 (s)-camptothecin. Cancer Res. 57:1997;1929-1933.
41. Williams J.A., Dillehay L.E., Tabassi K., et al. Implantable biodegradable polymers for IUDR radiosensitization of experimental human malignant glioma. J Neurooncol. 32:1997;181-192.
42. Ewend M.G., Williams J.A., Tabassi K., et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain models. Cancer Res. 56:1996;5217-5223.
43. Lana S.E., Dernell W.S., LaRue S.M., et al. Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet Radiol Ultrasound. 38:1997;474-478.
44. Dela Flor-Weiss E., Uziely B., Muggia F.M. Protracted drug infusions in cancer treatment An appraisal of 5-fluorouracil, doxorubicin, and platinums . Ann Oncol. 4:1993;723-733.
45. Spicer D.V., Ardalan B., Daniels J.R., et al. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res. 48:1988;459-461.
46. Howell S.B., Kirmani S., McClay E.F., et al. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Semin Oncol. 18:1991;5-10.
47. Markham M., Reichman B., Hakes T., et al. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer. 71:(Suppl.):1993;1565-1570.
48. Yu N.Y., Patawaran M.B., Chen J.Y., et al. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intra-tumoral drug delivery. Cancer J Sci Am. 1:1994;215-221.
49. Sipos E.P., Witham T.F., Ratan R., et al. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroxyperoxycyclophosphamide when administered locally in a rat glioma model. Neurosurgery. 48:1995;392-400.